Avanos Medical (AVNS) Net Income towards Common Stockholders (2013 - 2026)

Avanos Medical (AVNS) has 12 years of Net Income towards Common Stockholders data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders changed N/A year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 215.91% YoY), and the FY2024 full-year result was -$5.8 million, up 88.82% from the prior year.
• Net Income towards Common Stockholders advanced to $5.1 million in Q1 2026, from -$300000.0 in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $7.7 million in Q2 2022 to a low of -$63.8 million in Q2 2023.
• A 4-year average of -$2.1 million and a median of $4.7 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders surged 164.29% in 2022 and plunged 928.57% in 2023, its largest moves.
• Tracing AVNS's Net Income towards Common Stockholders over 4 years: stood at $7.2 million in 2022, then slumped by 106.94% to -$500000.0 in 2023, then jumped by 40.0% to -$300000.0 in 2024, then surged by 1800.0% to $5.1 million in 2026.
• Business Quant data shows AVNS's Net Income towards Common Stockholders at $5.1 million in Q1 2026, -$300000.0 in Q4 2024, and -$1.6 million in Q3 2024.